Understanding African American Donor Kidneys for Better Transplants
Trans-omics Analysis of African American Deceased Donor Kidneys for Transplant Outcomes.
['FUNDING_R01'] · WAKE FOREST UNIVERSITY HEALTH SCIENCES · NIH-11176080
This research aims to understand why some transplanted kidneys from African American donors with a specific gene variant fail faster, to help more people get successful kidney transplants.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WAKE FOREST UNIVERSITY HEALTH SCIENCES (nih funded) |
| Locations | 1 site (WINSTON-SALEM, UNITED STATES) |
| Trial ID | NIH-11176080 on ClinicalTrials.gov |
What this research studies
Many African Americans carry a gene variant called APOL1 that can lead to kidney disease and sometimes cause transplanted kidneys to fail sooner. However, not everyone with this variant develops severe problems, suggesting other factors are at play. This project looks closely at kidneys from African American donors to find these additional factors. By studying the genes and other biological markers in these kidneys, we hope to identify which donor kidneys are truly at higher risk and which ones are likely to do well. This knowledge could help doctors make better decisions about using these valuable donor kidneys.
Who could benefit from this research
Good fit: This research focuses on understanding donor kidneys and transplant outcomes for African American recipients, so future benefits would apply to African American individuals needing or receiving kidney transplants.
Not a fit: Patients who are not African American or who do not have the APOL1 gene variant may not directly benefit from the specific findings of this research.
Why it matters
Potential benefit: If successful, this work could lead to better ways to decide which donor kidneys are safe to use, potentially increasing the number of successful kidney transplants for African American patients and reducing health disparities.
How similar studies have performed: This project is an ancillary study to the existing national APOLLO network, which is already collecting data on APOL1 gene effects on transplant outcomes, building upon a foundation of ongoing research.
Where this research is happening
WINSTON-SALEM, UNITED STATES
- WAKE FOREST UNIVERSITY HEALTH SCIENCES — WINSTON-SALEM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FREEDMAN, BARRY IRA — WAKE FOREST UNIVERSITY HEALTH SCIENCES
- Study coordinator: FREEDMAN, BARRY IRA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.